Elastrin Therapeutics
Greenville, US · Founded 2017 · Delaware corporation · 1 known investors
Find your way into Elastrin Therapeutics
266 people in our graph share verified history with the Elastrin Therapeutics team — schools, employers, funds. One of them is your warm intro.
Nick Kalliagkopoulosunlockedknows Douglas Mulhall · together at Rotterdam School of Management, Erasmus University (overlapped)
knows the team · via University of Tübingen
×5knows the team · via Carleton University
×5knows the team · via University of Stuttgart
Elastrin Therapeutics is a biotechnology company developing therapies intended to reverse vascular calcification and restore arterial elasticity, targeting conditions such as heart attack, stroke and peripheral artery disease. Its platform uses nanoparticles with antibodies that bind to damaged elastin to deliver treatment specifically to sites of calcification, and it works with partners including the NIH and Clemson University.
Founders & leadership
Elastrin Therapeutics was founded in 2017 by Naren Vyavahare, Prof. Narendra Vyavahare, Ph.D., Douglas Mulhall, and Valentin Busch.
NV
Naren VyavahareCo-founder
PN
Prof. Narendra Vyavahare, Ph.D.Co-Founder & Chief Scientific Officer
DM
Douglas MulhallinCo-FounderDouglas Mulhall is co-founder of Elastrin Therapeutics and has previously served as co-founding CEO of Ukraine's first television and radio network and co-founder of an environmental institute focused on wastewater recycling in South America. He holds a research fellowship at Technische Universität München and has authored multiple books on technology and health.
VB
Valentin BuschinCo-Founder & Director of OperationsValentin Busch has over 10 years of experience in entrepreneurial and operational roles within technical organizations, including work as a consultant and co-founder advising biotech and deep-tech ventures on operations, fundraising, and organizational strategy. He is currently Co-founder and Head of Operations at Elastrin Therapeutics, a biotechnology company developing therapies to reverse vascular calcification.
SP
Shyam Parekh, Ph.D., MBAChief Executive Officer
MB
Matthias BreugelmansNamed on SEC filing
Board
PB
Patrick BurgermeisterBoard director
Investors · 1
Also in the syndicate · 1
KIZOO
Reported raises · per SEC filings
Form D private placements$13.3M disclosed across 5 rounds · 2021–2024
▶$500KraisedMar 2025 · 1 investors · BiotechnologyRule 506(b)
▶$500KraisedMar 2025 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Naren VyavahareExecutive Officer, Director
- Offering amount
- $500K
- Amount sold
- $500K
- First sale
- Sep 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2MraisedNov 2023 · 2 investors · BiotechnologyRule 506(b)
▶$2MraisedNov 2023 · 2 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Patrick BurgermeisterDirector
- Klaus-Dieter LangnerDirector
- Naren VyavahareExecutive Officer, Director
- Matthias BreugelmansExecutive Officer, Director
- Offering amount
- $2M
- Amount sold
- $2M
- First sale
- Aug 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$4.8MraisedNov 2023 · 3 investors · BiotechnologyRule 506(b)
▶$4.8MraisedNov 2023 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Matthias BreugelmansExecutive Officer, Director
- Naren VyavahareExecutive Officer, Director
- Klaus-Dieter LangnerDirector
- Patrick BurgermeisterDirector
- Offering amount
- $4.8M
- Amount sold
- $4.8M
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.5MraisedMar 2022 · 1 investors · BiotechnologyRule 506(b)
▶$2.5MraisedMar 2022 · 1 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Patrick BurgermeisterDirector
- Naren VyavahareExecutive Officer, Director
- Matthias BreugelmansExecutive Officer, Director
- Offering amount
- $2.5M
- Amount sold
- $2.5M
- Finders' fees
- $180.8K
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
▶$3.6MraisedMar 2022 · 3 investors · BiotechnologyRule 506(b)
▶$3.6MraisedMar 2022 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Matthias BreugelmansExecutive Officer, Director
- Naren VyavahareExecutive Officer, Director
- Patrick BurgermeisterDirector
- Offering amount
- $10M
- Amount sold
- $3.6M
- First sale
- Mar 2022
- Incorporated
- Corporation, Delaware, 2017
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2019 | $284K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
In the news
Frequently asked questions
- What does Elastrin Therapeutics do?
- Elastrin Therapeutics is a biotechnology company developing therapies intended to reverse vascular calcification and restore arterial elasticity, targeting conditions such as heart attack, stroke and peripheral artery disease. Its platform uses nanoparticles with antibodies that bind to damaged elastin to deliver treatment specifically to sites of calcification, and it works with partners including the NIH and Clemson University.
- Who founded Elastrin Therapeutics?
- Elastrin Therapeutics was founded by Naren Vyavahare, Prof. Narendra Vyavahare, Ph.D., Douglas Mulhall, Valentin Busch in 2017.
- How much funding has Elastrin Therapeutics raised?
- Elastrin Therapeutics has disclosed $13.3M raised across 5 rounds.
- Where is Elastrin Therapeutics headquartered?
- Elastrin Therapeutics is headquartered in Greenville, US.